Table 1. Detection of DNA mutations associated with isoniazid, rifampicin, ofloxacin and kanamycin resistance in two isolates from XDR-TB and pre-XDR-TB cases using GenoType MTBDRplus and GenoType MTBDRsl.
| Patient Nº | Collection period | MTBDRplus | MTBDRsl | ||||
|---|---|---|---|---|---|---|---|
| rpoB | katG | inhA | gyrA | rrs | embB | ||
| 1 | 2018 | MUT3 (codon 531) |
MUT1 (codon 315) |
WT | MUT3C (codon 94) |
MUT1 (codon 1401) |
MUT1B (codon 306) |
| 2 | 2018 | WT | MUT1 (codon 315) |
WT | WT3 missing (codon 92-97) |
WT | WT |
Point mutations in the rpoB gene confers resistance to rifampicin; katG gene and inhA gene promoter mutations confer resistance to isoniazid; the gyrA gene mutation confers resistance to fluoroquinolones; the rrs gene mutation confers resistance to kanamycin; the embB gene mutation confers resistance to ethambutol; WT = wild-type (no resistance); MUT = mutation (resistance) conferred by the gene mutation, with specific mutations indicated as number.